4-[2-(3-Oxo-butoxy)-ethoxy]-butan-2-one | 40941-86-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[2-(3-Oxo-butoxy)-ethoxy]-butan-2-one
• 英文别名: 4-[2-(3-Oxobutoxy)ethoxy]butan-2-one
• CAS: 40941-86-4
• 化学式: C₁₀H₁₈O₄
• 分子量: 202.251
• InChiKey: WKXICCBNYRFYFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES
  申请人：MERCK SHARP & DOHME CORP.

  公开号：EP3922260A2

  公开（公告）日：2021-12-15

  The present invention provides compositions comprising insulin receptor partial agonists or insulin dimers in association with GLP-1 analogues (e.g., liraglutide) as well as methods for using the compositions for example, to treat or prevent diabetes or to decrease body weight.

  本发明提供了由胰岛素受体部分激动剂或胰岛素二聚体与GLP-1类似物（如利拉鲁肽）组成的组合物，以及使用这些组合物治疗或预防糖尿病或减轻体重的方法。
• INSULIN RECEPTOR PARTIAL AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3221343B1

  公开（公告）日：2020-09-16
• MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION
  申请人：University of Copenhagen

  公开号：US20160176924A1

  公开（公告）日：2016-06-23

  The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated. Alternatively the compound of the invention comprises a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, where the first and second peptide or peptide analogue each comprise at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof.
• PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3
  申请人：MAX-PLANCK-GESELLSCHAFT ZURFÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US20160279224A1

  公开（公告）日：2016-09-29

  The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.
• VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 8
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US20170239341A1

  公开（公告）日：2017-08-24

  The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.